Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Trading Statement

5 Aug 2009 07:00

RNS Number : 8979W
PuriCore Plc
05 August 2009
 



PuriCore H1 2009 Trading Update 

Record Food Safety Shipments

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 5 August 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces a trading update covering the six months to 30 June 2009. Interim results for this period are expected to be announced on 25 August 2009. 

H1 2009 highlights:

Sales of $19.1 million, a decrease of 2% (an increase of 8% on a constant currency basis) (H1 2008: $19.5 million)

Food Safety sales of $12.6 million, an increase of 16%

Endoscopy sales of $6.1 million, a decrease of 27% (3% on a constant currency basis)

 

Cash balance as at 30 June 2009 of $15.8 million (increased from the cash balance as at 31 March 2009 of $15.6 million as a result of improved working capital and foreign currency)

Q2 operational cashflow positive

H1 operational cash outflow of $2.7 million (H1 2008: $4.8 million)

Debt reduced $2.7 million in H1 ($1.3 million in Q2)

 

Gross profit margins unchanged compared with H1 2008
Operating expense reductions of 14% (12% net of non-cash share compensation, depreciation and amortisation) compared with H1 2008 
Record 6-month shipments of 614 Sterilox Food Safety Systems

Post period-end developments (see separate release issued today):

Acquisition of Labcaire Systems Ltd., a leading UK supplier and manufacturer of endoscope disinfection equipment 

£2 million by way of a Placing through the issue of 10,810,811 Placing Shares at an Issue Price of 18.5 pence per share 

Outlook

PuriCore expects to complete the successful integration of Labcaire Systems into the business this year. The Company anticipates delivering full-year results for legacy PuriCore in line with market expectations for revenue growth and operating expenditure improvement. The Directors believe the Company is well positioned for further growth, and PuriCore will continue to make effective use of its balance sheet, including the strategic use of debt financing for leased systems.

Greg Bosch, Chief Executive of PuriCore, said:

 

"Wremain confident that we are well-positioned to execute on our legacy PuriCore business plan and look forward to integrating the Labcaire business in the UK as announced separately today."

Enquiries:

Ben Brewerton

Greg Bosch, CEO

Susan Quigley

Darren Weiss, VP of Finance

Financial Dynamics

PuriCore

+44 (0) 20 7831 3113

+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficileE.coli, HIV, Human and Animal Influenza (including H5N1 Avian Influenza), Legionella, MRSAM.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEASPSESFNEEE
Date   Source Headline
18th Aug 20167:00 amRNSBlock listing Interim Review
17th Aug 20167:00 amRNSPuriCore Receives Two U.S. Patents
16th Jun 201611:39 amRNSResult of AGM
9th Jun 20167:00 amRNSCompletion of Pre-IND Meeting with FDA on PR022
27th May 20167:00 amRNSResolution reached with EPA
14th Apr 20167:00 amRNSAppointment of Dr. Christian Peters as CMO
31st Mar 20167:00 amRNSNotice of AGM
29th Mar 20163:11 pmRNSDirector Dealing
29th Mar 20167:00 amRNSGrant of Options
24th Mar 20163:22 pmRNSAnnual Financial Report
24th Mar 20167:00 amRNSFinal Results
1st Mar 20167:00 amRNSAppointment of Dr Simba Gill to the Board
19th Feb 20169:30 amRNSBlocklisting Interim Review
8th Feb 20167:00 amRNSStrategic Review and Trading Update
4th Jan 201610:21 amRNSHolding(s) in Company
21st Dec 20158:55 amRNSHolding(s) in Company
14th Oct 20155:13 pmRNSDirector Dealing
30th Sep 20156:08 pmRNSHolding(s) in Company
28th Sep 20157:00 amRNSDirector Dealings
23rd Sep 20157:00 amRNSHalf Yearly Report
19th Aug 20158:33 amRNSBlocklisting Interim Review
1st Jul 20157:00 amRNSChange of Registered Office
19th Jun 20157:00 amRNSBoard Changes
18th Jun 201511:00 amRNSResult of AGM
9th Jun 20155:02 pmRNSGrant of Options
19th May 20157:00 amRNSAppointment of Alex Martin as CEO
2nd Apr 20157:00 amRNSDirector Dealing
31st Mar 20157:00 amRNSFinal Results
30th Mar 201512:22 pmRNSHolding(s) in Company
19th Mar 20157:00 amRNSSigns Major Supermarket Deal
24th Feb 20157:00 amRNSTrading Update
17th Feb 20158:24 amRNSBlocklisting Interim Review
9th Jan 20157:00 amRNSHolding(s) in Company
23rd Dec 20148:00 amRNSCancellation - PuriCore Plc
23rd Dec 20147:00 amRNSPuricore commences trading on AIM
25th Nov 20147:00 amRNSStrategic and Operational Review Update
24th Nov 20142:03 pmRNSResult of General Meeting
7th Nov 20147:00 amRNSProposed listing changes and notice of GM
5th Nov 20147:00 amRNSPuriCore granted two U.S. patents
31st Oct 20147:00 amRNSInterim Management Statement
14th Oct 20147:00 amRNSPlanned Directorate Changes
12th Aug 201411:49 amRNSDirector Dealing
11th Aug 20147:00 amRNSBlocklisting Interim Review
8th Aug 20147:00 amRNSHalf Yearly Report
31st Jul 20141:51 pmRNSNotice of Results
11th Jul 20147:00 amRNSTrading Update and Strategic Review
1st Jul 20147:00 amRNSCompletes Sale of UK Endoscopy Business
23rd Jun 20147:00 amRNSBoard Changes
20th Jun 201410:59 amRNSResult of General Meeting
19th Jun 201411:49 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.